{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:37:21Z","timestamp":1794328641643,"version":"4.9.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jviromet.2022.114640","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T12:10:49Z","timestamp":1667304649000},"page":"114640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Development of a sensitive, multi-assay platform to monitor low levels of HBV DNA and pgRNA in patients with chronic hepatitis B virus infection"],"prefix":"10.1016","volume":"311","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6152-9683","authenticated-orcid":false,"given":"Ran","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Colonno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Kitrinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2022.114640_bib1","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/JCM.00914-06","article-title":"COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma","volume":"45","author":"Allice","year":"2007","journal-title":"J. Clin. Microbiol."},{"issue":"Suppl. 1","key":"10.1016\/j.jviromet.2022.114640_bib2","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.jviromet.2022.114640_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00798-18","article-title":"Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients","volume":"92","author":"Bai","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2022.114640_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3748\/wjg.v13.i1.48","article-title":"Hepatitis B virus replication","volume":"13","author":"Beck","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jviromet.2022.114640_bib5","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.30082","article-title":"Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection","volume":"68","author":"Butler","year":"2018","journal-title":"Hepatology"},{"issue":"1915","key":"10.1016\/j.jviromet.2022.114640_bib6","first-page":"1016A","article-title":"Performance of an automated prototype assay for the detection & quantification of hepatitis B pregenomic RNA in chronic HBV patients receiving nucleos(t)ide analogue therapy","volume":"66","author":"Butler","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2022.114640_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(T)ide analogue therapy","volume":"72","author":"Carey","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2022.114640_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(17)31342-9","article-title":"Evaluation of serum HBV RNA and HBcrAg in chronic hepatitis B patients achieving different serological outcomes on tenofovir disoproxil fumarate (TDF)","volume":"66","author":"Cathcart","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2022.114640_bib9","doi-asserted-by":"crossref","first-page":"16459","DOI":"10.1038\/srep16459","article-title":"Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy","volume":"5","author":"Chen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jviromet.2022.114640_bib10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s40265-017-0769-2","article-title":"Drugs in development for hepatitis B","volume":"77","author":"Dawood","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jviromet.2022.114640_bib11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jviromet.2022.114640_bib12","doi-asserted-by":"crossref","first-page":"D566","DOI":"10.1093\/nar\/gks1022","article-title":"HBVdb: a knowledge database for hepatitis B virus","volume":"41","author":"Hayer","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jviromet.2022.114640_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01463-20","article-title":"Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731","volume":"64","author":"Huang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2022.114640_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2022.114640_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hep.510230303","article-title":"Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus","volume":"23","author":"Kock","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2022.114640_bib16","first-page":"61","article-title":"Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants","author":"Lam","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2022.114640_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010213","article-title":"Hepatitis B virus cure: targets and future therapies","volume":"22","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jviromet.2022.114640_bib18","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2022.114640_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30230-0","article-title":"LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients","volume":"70","author":"Ma","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2022.114640_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00535-021-01780-5","article-title":"Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy","volume":"56","author":"Mak","year":"2021","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.jviromet.2022.114640_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment. Pharm. Ther."},{"key":"10.1016\/j.jviromet.2022.114640_bib22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2022.114640_bib23","unstructured":"Organization, W.H., 2021. Hepatitis B. \u3008https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-b2021\u3009."},{"key":"10.1016\/j.jviromet.2022.114640_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12985-018-0994-7","article-title":"High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles","volume":"15","author":"Prakash","year":"2018","journal-title":"Virol. J."},{"key":"10.1016\/j.jviromet.2022.114640_bib25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.jviromet.2022.114640_bib26","first-page":"2005","article-title":"Circulating hepatitis B virus nucleic acids in chronic infection: representation of differently polyadenylated viral transcripts during progression to nonreplicative stages","volume":"7","author":"Su","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jviromet.2022.114640_bib27","first-page":"1477A","article-title":"Continued therapy with ABI-H0731\u2009+\u2009NrtI results in sequential reduction\/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg-positive patients","volume":"70","author":"Sulkowski","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2022.114640_bib28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2022.114640_bib29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/acsinfecdis.8b00191","article-title":"ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection","volume":"5","author":"Thi","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jviromet.2022.114640_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","author":"van Bommel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2022.114640_bib31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2022.114640_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.antiviral.2016.04.007","article-title":"Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors","volume":"131","author":"Zhang","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jviromet.2022.114640_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jmv.10464","article-title":"Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy","volume":"71","author":"Zhang","year":"2003","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jviromet.2022.114640_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: a pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antivir. Res."}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093422001884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093422001884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T10:55:50Z","timestamp":1759056950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093422001884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":34,"alternative-id":["S0166093422001884"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2022.114640","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a sensitive, multi-assay platform to monitor low levels of HBV DNA and pgRNA in patients with chronic hepatitis B virus infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2022.114640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114640"}}